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Abstract
Background: Granting dispensing pharmacists the authority to prescribe has significant implications for
pharmaceutical and health human resources policy, and quality of care. Despite the growing number of
jurisdictions that have given pharmacists such privileges, there are few rigorous evaluations of these policy
changes. This study will examine a January 2009 policy change in British Columbia (BC), Canada that allowed
pharmacists to independently adapt and renew prescriptions. We hypothesize this policy increased drug utilization
and drug costs, increased patient adherence to medication, and reduced total healthcare resource use.
Methods/Design: We will study a population-based cohort of approximately 4 million BC residents from 2004
through 2010. We will use data from BC PharmaNet on all of the prescriptions obtained by this cohort during the
study period, and link it to administrative billings from physicians and hospital discharges. Using interrupted time
series analysis, we will study longitudinal changes in drug utilization and costs, medication adherence, and short-
term health care use. Further, using hierarchical modelling, we will examine the factors at the regional, pharmacy,
patient, and prescription levels that are associated with prescription adaptations and renewals.
Discussion: In a recent survey of Canadian policymakers, many respondents ranked the issue of prescribing
privileges as one of their most pressing policy questions. No matter the results of our study, they will be important
for policymakers, as our data will make policy decisions surrounding pharmacist prescribing more evidence-based.
Background
Context
Access to primary care is an important concern for
patients in almost every jurisdiction examined. In
Canada, nearly 4 million individuals report not having a
regular physician and over 2 million report difficulties in
accessing routine or ongoing care [1]. For at least some
of these individuals, and for certain components of pri-
mary health care, non-physician health professionals
may represent high-quality alternatives. There is some
research evidence on the potential of deploying pharma-
cists in primary care [2]; that literature, and practical
experience in other jurisdictions points to a considerable
amount of untapped pharmacist human resources [3-7].
Expanding the scope of pharmacy practice may be a
cost-effective way to enhance patient access and adher-
ence to medicines, and to reduce the clinical burden on
primary care physicians.
Around 53% of Canadians fill one or more prescrip-
tions each year, and at least half of these represent
chronic medications used to manage cardiovascular risk
factors [8,9]. However, rates of continuous use of medi-
cines for chronic conditions are often sub-optimal [10].
But with prescription lengths limited to approximately 3
months in most provinces (with up to 4 refills if they
are provided), access to primary care doctors for the
purpose of prescription renewal may be a barrier to
continuous adherence to long-term drug therapies.
Thus, granting pharmacists prescribing authority may
increase Canadians’ access to medications. Though
pharmacists are highly trained in matters related to the
effects, interactions, and appropriate use of medicines,
their expertise is seldom called upon as a first-line pri-
mary health care provider in community settings.
Recently, numerous Canadian provinces have imple-
mented programs designed to expand the scope of phar-
macy practice. The first province to move in this
direction was Alberta, which implemented a program in
2007 that allows pharmacists to prescribe medications
and adapt existing prescriptions [3]. One year later,
three-quarters of pharmacists in the province reported
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[11]. Several other provinces allow pharmacists similar
prescribing privileges, and the remaining provinces have
passed the enabling legislation to allow pharmacist pre-
scribing in the future. The trend towards pharmacist
prescribing is present internationally as well. The United
Kingdom has introduced “independent prescribing”,
which gives pharmacists the ability to prescribe all med-
ications after completing a training program. Likewise,
in the United States, collaborative drug therapy manage-
ment by pharmacists is permitted by the federal govern-
ment and by at least 40 individual states [3]. All of these
changes granting pharmacists prescribing authority may
have significant implications for quality of care.
Policy Change: A Natural Experiment
A January 2009 policy change in the Canadian province
of British Columbia (BC) provides an opportunity to
generate valuable information about the impacts of
changes in pharmacists’ prescribing authority. This pol-
icy allowed pharmacists to adapt existing prescriptions
without the consent of the original prescriber [12]. The
policy was adopted based on the potential benefit of
increased patient adherence to medicines and an
expected reduction in the visit burden on primary care
physicians [13]. Prescription adaptations include chan-
ging the dose, regimen, or formulation of a prescription,
renewing an existing prescription and making therapeu-
tic substitutions to an alternative drug from the same
class. Therapeutic substitutions are only permitted in a
limited number of drug classes: histamine 2 receptor
blockers, non-steroidal anti-inflammatory drugs, nitrates,
angiotensin converting enzyme inhibitors, dihydropyri-
dine calcium channel blockers and proton pump inhibi-
tors. Further, pharmacists cannot modify the dose or
regimen for prescriptions treating cancer, cardiovascular
disease, asthma, seizures or psychiatric conditions.
Pharmacist-initiated renewal of a prescription involves
their dispensing of medicines beyond the term specified
in the original prescription. BC pharmacists are only
permitted to make renewals under certain circum-
stances. Renewals can only be made for patients with
long-term chronic conditions who have been on the
same therapy for more than six months. Further, phar-
macist-initiated renewals may only occur within the first
six months after an original prescription is filled. Phar-
macists cannot renew prescriptions for narcotics and
psychiatric medications. Finally, pharmacists are
required to notify the original prescriber of a renewal or
adaptation within 24 hours, and, although under no
obligation to participate, pharmacists who do so must
adhere to guidelines and possess two million dollars of
personal liability coverage.
Despite the fact that a growing number of jurisdic-
tions are giving pharmacists various forms of prescrip-
tive privileges, there are conspicuously few rigorous
evaluations of these policy changes. Allowing pharma-
cists to modify or renew prescriptions may or may not
improve treatment quality and continuity of care by
improving drug selection, dosing, and use [14] - this is a
testable hypothesis that has as yet not been convincingly
investigated. Therefore, we undertook a study to evalu-
ate pharmacist prescribing in BC. We hypothesized that
prescription adaptation by pharmacists increased drug
utilization and drug costs, increased patient adherence
to medication, reduced the use of ambulatory physician
services, and had no effect on hospitalization rates.
Methods/Design
Study Setting and Population
British Columbia (BC) is Canada’s westernmost and
third most populous province, with nearly 4.5 million
residents in 2009 [15]. Approximately half of the popu-
lation lived in the greater Vancouver area [16]. Our
study will focus on a population-based open cohort of
BC residents. In 2006, 14.7% of the population were
over 65 and 50.3% were female [17]. The population is
ethnically diverse, with significant numbers of people
identifying as Europeans, Aboriginals, East Asians, and
South Asians [18]. Thus, the overall population is typical
of that seen in the larger provinces of Canada and is
reasonably generalizable to many North American juris-
dictions. For all individuals, we will extract data on their
drug utilization as well as a range of control variables.
Based on prior work with the BC databases, we antici-
pate an overall cohort of over 4 million individuals,
which includes the majority of BC residents, with the
exception of First Nations and veterans who receive
drug benefits through the Federal Government.
Health care is provided to all residents through the
BC Medical Services Plan, which covers medically neces-
sary physician and hospital services. Unlike hospitals
and physicians, prescription drug coverage is a mix of
public and private programs. Public coverage is available
to all residents through the Fair PharmaCare program,
which covers prescription drugs after households have
met an income-based deductible. The public program
uses several cost containment mechanisms, including a
formulary of reimbursable medications and reference-
based pricing for several drug classes. Estimated provin-
cial health expenditure in 2009 was $23.4 billion, about
$2.6 billion of which paid for prescription drugs [19,20].
In sum, this public expenditure represented about 42%
of total drug costs [20]. Alongside this public coverage,
many BC residents hold private drug coverage, largely
paid for through their employer.
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maintain regular communication with local and national
decision makers. This research project was developed in
collaboration with the BC Ministry of Health Services
and upon consultation with the BC Pharmacy Associa-
tion, so we expect the results will affect future policy
development or the refinement of existing policies. This
study was reviewed and approved by the University of
British Columbia Behavioural Research Ethics Board.
Data Sources
Data Access and Linkage
Three population-based, administrative data sources will
be used in this analysis: (1) the BC PharmaNet prescrip-
tion drug claims database, and (2) health services utiliza-
tion databases held at Population Data BC. We plan to
study data for a period of 5 years prior to the policy and
2 years after (January 1, 2004 through December 31,
2010).
The Databases
BC PharmaNet
Pharmaceutical dispensing data come from the prescrip-
tion monitoring system-BC PharmaNet-that was estab-
lished in 1995 to track progress toward deductibles
under the BC PharmaCare program, and to monitor for
contraindicated combinations of prescribed drugs. It
contains a comprehensive record of ambulatory pre-
scriptions received by all residents of the province. The
PharmaNet database will be used to capture data on
individual prescriptions, including drug type, total cost,
whether the prescription is a physician-initiated refill,
and whether the prescription was adapted or renewed
by a pharmacist. The design of the PharmaNet database
makes it possible to ‘nest’ all prescriptions according to
the originating pharmacy; this information will be used
to determine the characteristics of the originating phar-
macy such as the volume of prescriptions. These data-
bases have been used extensively in pharmaceutical
policy and pharmacoepidemiology research, and are
considered to be among the most valid and highest
quality available in Canada [21-23].
Health Services Data from Population Data BC
Health services data holdings of Population Data BC
include administrative data files containing information
from medical service claims submitted by physicians,
hospital separations, and vital statistics (births/deaths).
Specific information to be drawn from these data
sources for the purposes of this project will include the
following: from the Medical Services Plan registration
files, descriptive information about individuals in the
study population (age, sex, Local Health Area, duration
of residency); from the Medical Services Plan payment
file, medical services used and data for the construction
of profiles of patient morbidity ICD-9 codes); from the
Hospital Separations files, data for the construction of
measures of patient morbidity and clinical complexity
(discharge data and up to 25 primary and secondary
ICD-10 diagnosis codes); and from the Vital statistics,
date of death.
Income Data
For each individual, we will assign income percentiles
using existing custom tabulations of Statistics Canada’s
Taxfiler Database at the Census Dissemination Area
level [24]. In previous studies, these data have shown
reasonable agreement with individual-level verified
incomes [25].
General Work Plan
For various components of the analysis, we will use spe-
cific subsets of prescription drug claims. First, we will
use data on all prescriptions to analyse the prevalence
and characteristics of pharmacist adaptations and
renewals and their overall impact on drug utilization
and costs. Second, we will study all prescriptions from
drug classes in which adaptation was permitted. Third,
we will determine prescriptions that were ‘potentially
renewable’. The guidelines for pharmacist renewal state
that a prescription may be renewed for a medication
used for a chronic condition that the patient has used
for more than 6 months with no changes. Thus, we will
define a ‘potentially renewable’ prescription-one that a
pharmacist could have hypothetically renewed-using the
following criteria (see Figure 1):
1. At least one prescription for the same drug during
the period from 2 years prior to six months prior, to
establish long-term “consistent use” (prescription J-2)
2. One or more prescriptions for the same drug dur-
ing the 6 months prior to the current prescription
(prescription J-1)
3. The potentially renewable prescription, prescrip-
tion J, is for the same drug at the same dose as pre-
scription J-1.
Subgroup Analyses
To study the impact of prescription renewal on adherence
to therapy and short-term health care use, we will con-
struct cohorts of patients established on specific medica-
tions. We will study users of medication classes that are
typically used continuously, such as anti-hypertensives,
and are amongst the top 20 classes of drugs in terms of
the number of users in BC [26]. We will exclude medica-
tion classes that pharmacists are restricted from renewing
or where pharmacist renewal is unnecessary given existing
dispensing rules. Based on data from the BC Rx Atlas, 2nd
Edition, Table 1 shows the approximate numbers of
unique users of specific drug classes to be studied [26].
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Prescription Rate
Our analysis of drug utilization will focus on both the
number of Defined Daily Doses (DDDs) of particular med-
ications and the number of days supplied. Days supply is a
field that must be entered by pharmacists in the Pharma-
Net database for the prescription dispensation to be adju-
dicated under the universal, income-based drug benefit
program. DDDs are a WHO-developed measure that stan-
dardizes drug therapy and provides a consistent measure
of drug use over time between therapies with different
typical dosing levels [27]. Using DDDs will allow us to
assess the validity of the days supplied field.
Costs
We will examine the cost of pharmacist adaptations and
renewals by studying the drug cost per eligible patient,
along with the professional fees paid to pharmacists for
performing adaptations and renewals. For adaptations,
we will analyze any changes in the cost per day of treat-
ment within specific therapeutic classes. Of particular
interest will be any shifts toward use of less expensive
alternative drugs under BC PharmaCare’s Reference Pri-
cing Program [28-30]. For renewals, we will examine the
impact on drug costs due to increased drug adherence.
Medication Adherence
We will analyse prescription adherence using two com-
monly used measures [10]. The first measure is the pro-
portion of days covered, which is the number of days
supply of medication divided by the number of days in
each study month. Second, we will construct measures
of persistence, defined as the number of days of therapy
without a gap of 90 or more days.
Ambulatory physician visits
To assess the impact of the policy changes in the visit
burden on primary care physicians, we will analyse the
number of ambulatory physician care visits per patient
per month, for patients prescribed each renewal or
adaptation-eligible class of drug. While it would be ideal
to study visits that were only intended to renew a pre-
scription, billing data do not contain sufficient detail.
Hospital Admissions
To assess any changes in hospitalization rates, we will
analyse the number of hospital admissions for relevant
diagnoses (i.e. myocardial infarction for antihypertensive
users).
Other Variables
Demographic characteristics
For modelling the determinants of prescription adaptation
and renewal, we will include indicators for patient age,
sex, urban/rural, and socioeconomic status (income level).
To define urban and rural areas, we will divide BC Local
Health Areas (LHAs) based on population density using
existing publically available data [31]. Income level will be
derived from Statistics Canada data, as described above.
Case-mix Adjustment
We will adjust for case-mix in resource consumption at
the individual level in our models using the John’s Hop-
kins ACG Case-Mix System [32].
Pharmacy and Pharmacist prescribing volume
For each pharmacy and pharmacist in our sample, we
will calculate average prescribing volumes over the
study period by dividing the total number of prescrip-
tions by the number of months.
Proposed Statistical Analysis
Descriptive Characteristics of Adaptations
We will use the complete population-based cohort of
prescriptions to detail the following descriptive charac-
teristics of adaptations for the first year of the program:
1. Number and types of adaptations performed;
Figure 1 Definition of a “Potentially Renewable Prescription” (J). The solid circles are examples of prescriptions that must have been filled:
one prior to six months before the potentially renewable one (J-1) and one in the 18 months prior to that (J-2). The outlines represent
examples of other possible prescriptions during the same time periods.
Table 1 Number of unique users in potential drug classes
for analysis in 2006
Drug Class Unique users in 2006
Cardiovascular: Antihypertensives 587,814
Psychiatric: Antidepressants 382,813
Acid reducing drugs 316,738
Cardiovascular: Statins 284,364
Hormonal contraceptives 204,629
Diabetes: Oral drugs (non-insulins) 128,408
Bisphosphonates 100,944
Cardiovascular: Antithrombotics 82,136
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regularly adapted;
3. The concentration of adaptations amongst particu-
lar pharmacists, particular pharmacies and particular
geographic regions;
4. The cost of professional services fees for the adapta-
tion program.
Impact of Pharmacist Adaptation
Using Interrupted Time Series Analysis, we will study
longitudinal changes in drug utilization and costs, medica-
tion adherence, and ambulatory care visits and hospitaliza-
tions during each study month [33]. Our models will take
the following form to model each measure in month i:
outcome time policy policy time ii i i i =+ + + +     01 12 3 ·· · ·
Where time represents the month in study time (i.e. 1,
2, 3...) and policy is an indicator variable indicating if the
policy is in effect at that observation point. The two para-
meters of interest are b2, which indicates any immediate
change in the level of the outcome and b3, which indi-
cates any change in the trend of the outcome following
initiation of the policy. As the monthly observations may
be correlated over time, we will control for autocorrela-
tion using appropriate adjustments in a generalised least
s q u a r e sm o d e l ,o ras i m i l a rm o d e lf o rc o r r e l a t e dd a t a
[33]. We will use the resulting model estimates to calcu-
late both absolute and percentage changes in the out-
comes to make the results easily interpretable [34].
As the policy may have had differential uptake rates
amongst particular pharmacists, we will also explore
constructing a “control” c o h o r tf o rt h i sa n a l y s i si ns e v -
eral ways. For example, we will explore the utility of
stratifying our sample into two groups: patients that vis-
ited a pharmacy that adapts prescriptions, and patients
that did not. This would allow us to more specifically
identify an effect by having a control series in all our
time series regressions and perhaps to determine if
“early adoptors” are representative of the pharmacist
population in general. Alternately, we may explore using
propensity score matching to pair individuals who had a
prescription adapted with otherwise similar individuals
who did not [35] or instrumental variables analysis.
Determinants of Pharmacist Adaptations and Renewals
We will use multi-level modelling techniques to deter-
mine what factors at the region, pharmacy, patient and
prescription levels are associated with prescription adap-
tations and renewals. In particular, we will investigate
systematic differences in how the policy has affected
patients of different age, sex and socioeconomic status.
For example, we know that drug use varies by sex; for
instance, there are higher rates of antidepressant use
amongst women in Canada [36]. Thus, it may be that
this policy has differential effects on men and women.
Further, one identified goal of the policy was to increase
access to medicines in rural communities. Thus, we will
investigate rural region as a key factor.
By using a hierarchical model to model the probability
of an adaptation or renewal, we can estimate the effect
of different region, pharmacy, and patient characteristics
while controlling for the clustering of observations
within these different levels. For the determinants asso-
ciated with adaptation, we will use the dataset contain-
ing all prescriptions for drugs potentially subject to
adaptation. For renewals, we will use the dataset of
potentially renewable prescriptions described above.
Our model will contain a hierarchical structure of 4
levels and include the following variables:
￿ Regional characteristics (of ~79 regions with suffi-
cient population size): urban/rural; primary care
physician supply (per 10,000 population); average
income
￿ Pharmacy characteristics: chain/independent; num-
ber of pharmacists; volume of prescriptions, patients,
and prescribers
￿ Patient characteristics: patient age, sex, health sta-
tus, income
￿ Prescription characteristics: drug class; length of
prescription; calendar month (to control for
seasonality)
When modelling, we will test intra-cluster correlation
coefficients to determine which levels of the hierarchical
structure are important.
In both analyses, we will control for clustering at each
level by appropriately including random effects terms in
the model. As the primary goal of our modelling strat-
egy is to test for differences between types of LHAs (i.e.
urban/rural) and not for differences between individual
LHAs, we have chosen to use random effects rather
than fixed effects models. Our models will thus have the
following general structure to model the probability of
adaptation or renewal:
Pr adaptation yes X X X b b b ijk ij k i j k = () =+ + + + ++ +     01 2 3        i ijk
where Xi, Xj, Xk and Xl are vectors of variables asso-
ciated with LHA i,p h a r m a c yj,p a t i e n tk and prescrip-
tion l, respectively, and bi, bj,a n dbk are random effects
terms to account for multiple prescriptions from the
same LHA i, pharmacy j and patient k.
Discussion
Using a prospective population-based cohort study
and interrupted time series analyses, we plan to take
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respect to pharmacist adaptation and renewal. Short of
a randomized trial, our proposed approach has perhaps
the highest level of internal validity that could be
brought to bear to answer such an important policy
question. Our analysis will benefit from having compre-
hensive population-based data on every prescription for
the majority of the BC population, something that is not
possible in other Canadian jurisdictions with similar
policies in place. Despite its novelty and strengths, we
recognize several limitations.
Study Limitations
First, while our study methodology is based on a
strong quasi-experimental research design, individual
patients could not feasibly be randomized to treatment
(as in a controlled trial). While it might have been pos-
sible to randomize the pharmacists themselves to when
they could begin using their advance prescribing privi-
leges, this was not part of the policy implementation.
Second, our study will be limited to administrative
health data, and as such will not contain detailed clini-
cal data that might be obtained through medical
records. Third, we will have limited measures regard-
ing the appropriateness of prescribing and patient or
physician or pharmacist satisfaction. Finally, we will
not have access to data on over-the-counter medica-
t i o n su s e .T h i sw i l lo n l yb eap o t e n t i a li s s u ef o rt h e
few drug classes where there are over-the-counter
equivalents, such as acid-suppressing drugs. However,
as many individuals have low deductibles under BC’s
Fair PharmaCare program, the prescription alternative
will be less costly for many individuals with regular
drug use.
Conclusion
In a recent survey of Canadian policymakers, many
respondents from across the country ranked the issue of
prescribing privileges as one of their most pressing pol-
icy questions [37]. No matter the results of our study,
they will be important for policymakers. If we find the
policy is safe and effective and cost-neutral, it will pro-
vide justification for widespread adoption elsewhere and
provide justification for it’sc o n t i n u a t i o ni nB C .I fi t
leads to substantially increased drug costs or health care
use, it may need to be significantly altered or aban-
doned. However, our study findings will make such
decisions evidence-based, and help inform other health-
care jurisdictions.
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